http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2006145548-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_841696694d77c83b98450192f17c29ed |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N11-167 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N11-162 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-86 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-352 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-15 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-49 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N11-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-46 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-195 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-86 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-197 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-727 |
| filingDate | 2005-12-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1e085080f75fe28d4f61c038605aae46 |
| publicationDate | 2006-06-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2006145548-A |
| titleOfInvention | Method and apparatus for monitoring antiplatelet agents |
| abstract | A method for measuring the efficacy of an antiplatelet agent continuously from the initial clot formation to dissolution and over the entire coagulation process is provided. A blood coagulation analyzer is provided, the blood coagulation analyzer being capable of measuring clot strength; Using the blood coagulation analyzer to measure a first blood coagulation parameter of a first blood sample obtained in the absence of antiplatelet therapy; Measuring a second blood coagulation parameter of a second blood sample obtained in the presence of antiplatelet therapy using the blood coagulation analyzer; Here, at least one of the first blood coagulation parameter and the second blood coagulation parameter prevents the characteristics of the as-sampled portion of each blood sample and thrombin activation and activation of fibrinogen and platelets. Based on the characteristics of a portion of each blood sample treated in vitro to protect; and based on the first and second blood clotting parameters, the efficacy of the antiplatelet agent is measured. [Selection] Figure 3 |
| priorityDate | 2000-06-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 100.